United States - English - NLM (National Library of Medicine)

rebel distributors corp - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 6 mg - invega® (paliperidone) extended-release tablets are indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14)] . monotherapy invega® (paliperidone) extended-release tablets are indicated for the acute treatment of schizoaffective disorder as monotherapy. adjunctive therapy invega® (paliperidone) extended-release tablets are indicated for the acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone. invega® (paliperidone) is a metabolite of risperidone and is therefore contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in invega® . pregnancy category c . there are no adequate and well controlled studies of invega® in pregnant women. invega® should be used during pregnancy only if the potential benefit jus

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - paliperidone palmitate 156 mg/ml - eq. paliperidone 100 mg/ml (pre-filled syringe 150 mg); paliperidone palmitate 156 mg/ml - eq. paliperidone 100 mg/ml (pre-filled syringe 100 mg) - prolonged-release suspension for injection - 150 mg + 100 mg - paliperidone palmitate 156 mg/ml; paliperidone palmitate 156 mg/ml - paliperidone

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - paliperidone - prolonged-release tablet - 3 milligram(s) - paliperidone

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - paliperidone - prolonged-release tablet - 6 milligram(s) - paliperidone

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - paliperidone - prolonged-release tablet - 9 milligram(s) - paliperidone

Canada - English - Health Canada

mylan pharmaceuticals ulc - paliperidone - tablet (extended-release) - 3mg - paliperidone 3mg - atypical antipsychotics

Canada - English - Health Canada

mylan pharmaceuticals ulc - paliperidone - tablet (extended-release) - 6mg - paliperidone 6mg - atypical antipsychotics

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.